Advanced Cell Diagnostics

Executive Summary

Advanced Cell Diagnostics (ACD) is a privately held biotechnology company headquartered in Newark, United States, specializing in the development and commercialization of RNAscope, a proprietary in situ hybridization (ISH) technology. This platform enables the visualization and analysis of RNA biomarkers at single-cell resolution within intact cells and tissues, offering high sensitivity and specificity. ACD provides a vast catalog of over 40,000 validated probes covering more than 400 species, along with rapid custom probe development services, positioning itself as a key player in the fields of genetics and genomics for both research and diagnostic applications. Founded in 2006, the company has established a strong foothold in the life sciences tools market, serving academic institutions, pharmaceutical companies, and clinical research organizations seeking to understand gene expression patterns in spatial context. As the demand for spatial biology and multiplexed RNA detection grows, ACD is well-positioned to capitalize on trends in precision medicine and biomarker discovery. The company's RNAscope technology is increasingly adopted in translational research and clinical diagnostics, particularly in oncology and neuroscience. While ACD remains private and financial details are undisclosed, its proprietary platform and extensive probe library create significant barriers to entry. Potential catalysts include the expansion of its product portfolio into high-throughput and multiplexed assays, strategic partnerships with diagnostic firms for clinical adoption, and advancements in spatial biology offerings. The company's continued innovation and market expansion are expected to drive growth, though competition from emerging spatial transcriptomics technologies may pose challenges.

Upcoming Catalysts (preview)

• Q3 2026Launch of New Multiplex RNAscope Assays for Oncology Biomarkers80% success
• 2026Strategic Partnership with Major Diagnostic Company for Clinical Adoption60% success
• 2027Expansion into Spatial Biology with Integrated Multi-omics Platform50% success